← Studies & programmes
Emerging treatmentsFirst study in people — mainly checks safetyAccepting participants
KITE-363 early cell-therapy study including MS
Published by MyelinWatch:
KITE-363 early cell-therapy study including MS · KITE-363 uses a person's own T cells, modified to recognise B cells carrying CD19 or CD20, in a study of refractory autoimmune neurological diseases including MS.
What is being studied
KITE-363 uses a person's own T cells, modified to recognise B cells carrying CD19 or CD20, in a study of refractory autoimmune neurological diseases including MS.
Research stage
First study in people — mainly checks safety
The current listing is open to participants.
What we know so far
The Phase 1a/1b registry entry says the study is accepting participants; that entry has no posted results.
What this means for patients today
It is a study, not an available proven MS treatment; places and eligibility must be confirmed with the team.
- Treatment or approach
- KITE-363 early cell-therapy study including MS
- Where the study is running
- Listed locations have no Greek site; this does not establish broader Greek treatment access.
- Published by MyelinWatch
- Last substantive MyelinWatch update